Search
regadenoson (Lexiscan)
Indications:
- stress agent for patients unable to undergo exercise stress testing (myocardial perfusion scintigraphy) Contradindications:
- may cause bronchospasm, use with caution in patients with asthma or COPD*
* according to [4] (NEJM) regadenoson may be used in patients with stable COPD without active bronchospasm
Adverse effects:
- rare but serious risk of myocardial infarction & death [3]
Mechanism of action:
- presumptively vasodilator (by analogy to persantine)
Notes: Manufacturer: Astellas Pharma
Interactions
drug adverse effects of antihypertensive agents
General
vasodilator agent
Database Correlations
PUBCHEM cid=219024
References
- Prescriber's Letter 16(2): 2009
New Drugs Approved by the FDA in 2008
Detail-Document#: 250213
(subscription needed) http://www.prescribersletter.com
- Al Jaroudi W, Iskandrian AE.
Regadenoson: a new myocardial stress agent.
J Am Coll Cardiol. 2009 Sep 22;54(13):1123-30
PMID: 19761931
- FDA MedWatch. Nov 20, 2013
Lexiscan (regadenoson) and Adenoscan (adenosine): Drug Safety
Communication - Rare but Serious Risk of Heart Attack and Death.
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm375981.htm
- NEJM Knowledge+ Complex Medical Care